The accumulation of metabolic syndrome components is associated with higher risk of positive surgical margin among patients with localized prostate cancer after radical prostatectomy
Received 19 November 2018
Accepted for publication 29 January 2019
Published 26 February 2019 Volume 2019:12 Pages 1613—1620
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Leo Jen-Liang Su
Xiaonan Zheng,1,* Shi Qiu,1,2,* Xinyang Liao,1 Xin Han,3 Kun Jin,1 Lu Yang,1 Qiang Wei1
1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3West China Medical School, Sichuan University, Chengdu, Sichuan, People’s Republic of China
*These authors contributed equally to this work
Objective: To evaluate the association between metabolic syndrome (MetS) and the accumulation of its components with prostate cancer (PCa).
Patients and methods: Patients undergoing radical prostatectomy were retrospectively included. Patients were grouped by low risk and intermediate-high risk according to International Society of Urological Pathology grade. Multivariable logistic regression and Cox hazard regression model were utilized to assess the association of MetS with overall survival, biochemical recurrence, upgrading, upstaging, and positive surgical margin (PSM) after prostatectomy. Besides, trend test was also performed to evaluate the impact of the accumulation of MetS components on postoperative pathological feature.
Results: A total of 1,083 patients were eventually enrolled. With a median follow-up of 40.45 months, 197 patients were diagnosed with MetS. No significant association between MetS and survival outcomes and pathological features was found. However, we did notice that the accumulation of the MetS components could lead to an elevated gradient of the PSM risk in the entire cohort (one component: OR=1.46; two components: OR=1.89; ≥3 components: OR=2.07; P for trend=0.0194) and intermediate-high risk group (one component: OR=1.4; two components: OR=1.85; ≥3 components: OR=2.05; P for trend=0.0127).
Conclusion: The accumulation of MetS components could lead to increasing risk of PSM on the entire PCa cohort and patients with intermediate-high risk PCa after prostatectomy, but not for the low-risk patients.
Keywords: prostate cancer, PCa, metabolic syndrome, MetS, International Society of Urological Pathology, ISUP, positive surgical margin, PSM
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]